Which organisms are commonly co‑isolated with Escherichia coli in urinary tract infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Organisms Commonly Co-Isolated with E. coli in UTIs

E. coli is most commonly co-isolated with Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus in urinary tract infections. 1

Primary Co-Pathogens

The bacterial landscape of UTIs shows a consistent pattern of organisms that accompany E. coli:

  • Klebsiella pneumoniae is the second most common uropathogen found alongside E. coli, particularly in complicated UTIs and healthcare-associated infections 1, 2

  • Proteus mirabilis frequently co-exists with E. coli, especially in patients with structural urinary tract abnormalities or catheter-associated infections 1

  • Enterococcus faecalis represents another common co-pathogen, particularly in polymicrobial infections and in patients with instrumentation or recent antibiotic exposure 1

  • Staphylococcus saprophyticus is commonly identified alongside E. coli, particularly in young sexually active women with uncomplicated cystitis 1

Clinical Context

While E. coli accounts for up to 90% of all UTIs in ambulatory populations as a single pathogen 3, when polymicrobial infections occur, the organisms listed above represent the most frequent co-isolates 1.

Important Considerations:

  • E. coli dominance: In most UTI cases, E. coli is the predominant organism even when other bacteria are present, with uropathogenic E. coli (UPEC) being the primary driver of infection 1

  • Antimicrobial resistance patterns: Co-infections with these organisms increasingly involve multidrug-resistant strains, particularly ESBL-producing Enterobacterales (E. coli and Klebsiella) 2

  • Treatment implications: When treating suspected polymicrobial UTIs, empiric coverage must account for both E. coli and these common co-pathogens, with consideration of local resistance patterns 2

Related Questions

What is the best treatment approach for an 85-year-old female with Escherichia coli (E. coli) urinary tract infection (UTI)?
What is the recommended antibiotic regimen for a male patient with an E. coli (Escherichia coli) urinary tract infection (UTI)?
What is the management for a 2-year-old child with a first episode of Escherichia coli (E. coli) urinary tract infection (UTI) and mild hydronephrosis?
How should I treat an 84-year-old female with a urinary tract infection due to Escherichia coli, given pyuria, nitrite negative, bacteria and yeast on microscopy, and a urine culture growing greater than 100,000 colony‑forming units per milliliter?
What is the recommended treatment for an elderly female with recurrent Escherichia coli (E. coli) urinary tract infections (UTIs)?
What antihypertensive agents can be safely used in a patient taking risperidone, avoiding additive orthostatic hypotension and CYP2D6 interactions?
What is the correct intravenous infusion protocol for zoledronic acid (Reclast/Zometa) in a patient with creatinine clearance ≥35 mL/min, normal serum calcium, and no bisphosphonate hypersensitivity, including pre‑hydration, dose selection, dilution in 0.9 % sodium chloride, infusion duration, monitoring, and post‑infusion care?
What is the appropriate treatment for an adult rash with active lesions or pustules?
What captopril dosage is appropriate for a hypertensive urgency patient with systolic blood pressure 200 mm Hg, headache, no end‑organ damage, who is currently taking risperidone?
What baseline assessments and ongoing monitoring (vital signs, laboratory tests, infusion rates, and adverse‑effect surveillance) are required for a patient receiving intravenous immunoglobulin (IVIG) therapy?
What is the recommended management for a patient with multiple lipomas?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.